Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective unilateral total knee replacement for primary osteoarthritis of knee~* ASA (American Society of Anesthesiologists) grading 1 or 2~Exclusion Criteria:~* Rheumatoid arthritis or seronegative arthritis~* Allergy to any medications used in the standard protocol (Methylprednisolone, adrenaline, ropivacaine, ketorolac, bupivacaine, ketorolac, pepcidine, transamin, gabapentin, voltaren, panadol, DF118)~* Chronic opioid use~* Substance dependence~* Patients attending chronic pain clinic~* Psychiatric or neurological condition that may influence pain perception or reporting~* Chronic illness that preclude the use of the medications in the standard protocol~* Hepatitis B carrier or Elevated bilirubin or ALT~* Active peptic ulcer disease~* Uncontrolled diabetic patients with HbA1c \>7% in recent 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone Group (Type: EXPERIMENTAL): The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
- Placebo Group (Type: PLACEBO_COMPARATOR): The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).